RecruitingNCT06467383
A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
Sponsor
MSD Italia S.r.l.
Enrollment
600 participants
Start Date
Jun 25, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a non-interventional, retrospective observational study to improve knowledge regarding the diagnosis and treatments of patients who have/had non-small cell lung cancer (NSCLC), either early stage (stage I-II).
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is looking back at the records of patients with early to locally advanced non-small cell lung cancer (NSCLC) who received surgery or radiation with curative intent, to understand how their disease was diagnosed, treated, and how they fared over time.
**You may be eligible if...**
- You are 18 or older
- You were diagnosed with stage I, II, or III non-small cell lung cancer between January 2018 and June 2019
- You received surgery or radiation with curative intent
- Your medical records with follow-up through January 2021 are available
**You may NOT be eligible if...**
- Your medical records are unavailable or incomplete for the required time period
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(25)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06467383
Related Trials
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT0718599778 locations
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
NCT066944541 location
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT0755433950 locations
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT0751337646 locations
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
NCT0743182772 locations